Silver Scott Health, Inc. to Offer DNA Vibe's Award-Winning Patented Light Therapy Devices
FRANKLIN, NJ / ACCESS Newswire / June 24, 2025 / Silver Scott Health, Inc., a division of Silver Scott Mines, Inc. (OTC PINK:SILS), today announced a distribution agreement with DNA Vibe, the innovator behind patented red light therapy devices. Beginning in the third quarter, DNA Vibe's wearable wellness technology will be available for purchase on the Silver Scott Health website, furthering the company's mission to bring scientifically-backed, non-invasive health and wellness solutions to consumers. The product will be available initially on affordabletelehealthplan.com and will expand to other sites owned by Silver Scott Health, Inc.
DNA Vibe's 'Jazz Band' certified wellness technology uses a unique combination of red light, infrared, magnetic pulse, and micro-vibration technology to support pain relief, reduce inflammation, and accelerate recovery-all without drugs or invasive procedures. The Jazz Band has garnered enthusiastic support from professional athletes and elite trainers, health professionals, and wellness advocates, along with more than one-hundred thousand Moms, Dads, Grandparents and Kids living happier, healthier, more active lives.
'Partnering with DNA Vibe allows Silver Scott Health to expand into the fast-growing, multi-billion-dollar market of wearable therapeutic technologies,' said Stuart Fine, spokesperson for Silver Scott Mines, Inc. 'This addition strengthens our portfolio and positions us to meet rising consumer demand for accessible, at-home health solutions.' DNA Vibe's technology is not only the most advanced wellness wearable available, it is proudly made in the USA via a transformational community-based manufacturing model, as DNA Vibe aims to make its products in and with the communities it serves.
With the global red light therapy market expected to exceed $1.1 billion by 2030, Silver Scott Health is strategically aligning itself with breakthrough wellness solutions that are both effective and scalable.
Silver Scott Mines, Inc. (Franklin, NJ), through its health division, continues to seek innovative partnerships and product lines that reflect its commitment to health, longevity, and value creation for shareholders.
About Silver Scott Mines, Inc.
Silver Scott Mines, Inc. (OTC: SILS) is a diversified company with interests in health, technology, and natural resources. Through its health division, Silver Scott Health, Inc., the company aims to deliver cutting-edge wellness products that align with the growing demand for preventative and personalized care.
About DNA Vibe
DNA Vibe is a science-backed wellness company specializing in wearable light therapy technology. Its flagship product, the Jazz Band, is used by professional athletes, medical professionals, and everyday people seeking relief and recovery through safe, non-invasive methods. A Veteran-founded company, DNA Vibe's technologies are uniquely and proudly made in the USA.
For Investor Relations Contact:
Stuart Fine Silver Scott Mines, Inc. Phone: 908-356-9852 Website: Twitter: @silverscottmine @TrustNFT2025
Forward-Looking Statements:
This press release includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. Words such as expects, believes, anticipates, intends, estimates, seeks and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Silver Scott Mines are based on current expectations that are subject to risks and uncertainties.SOURCE: Silver Scott Mines Inc
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
2 hours ago
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Business Upturn
2 hours ago
- Business Upturn
RECKITT (RBGLY) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Reckitt (RBGLY) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Reckitt between January 13, 2021, and July 28, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Reckitt Benckiser Group plc ('Reckitt' or the 'Company') (OTC:RBGLY) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Reckitt securities between January 13, 2021, and July 28, 2024, both dates inclusive (the 'Class Period'). Investors have until August 4, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Reckitt is a United Kingdom-based, global consumer goods company. To date, over 500 state and federal products liability lawsuits have been filed against Reckitt and its competitor, Abbott Laboratories ('Abbott'), claiming that they failed to adequately warn that premature infants consuming cow milk-based formulas, such as Reckitt's Enfamil and Abbott's Similac, have an increased risk of developing necrotizing enterocolitis ('NEC'), a life-threatening intestinal disease that affects premature or low birth weight infants. The Class Action alleges that, during the Class Period, Defendants made misleading statements and omissions regarding the Company's business, financial condition, and prospects. Specifically, Defendants failed to warn investors and consumers: (1) that preterm infants were at an increased risk of developing NEC by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Reckitt shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
